News

AbstractThis viewpoint highlights the critical need for a standardized definition of heart failure (HF) endpoints in clinical trials specific to transthyretin…

AbstractCardiac immunoglobulin light chain (AL) amyloidosis classically presents with biventricular heart failure and increased wall thickness. Recurrent unilateral…

AbstractBackground: Transthyretin amyloidosis with cardiomyopathy (ATTR-CM) is underdiagnosed in heart failure with preserved ejection fraction. Although disease-…

AbstractBackgroundTransthyretin amyloid cardiomyopathy (ATTR-CM) coexists in up to 15% of elderly patients with severe aortic stenosis (AS), presenting complex…

HighlightsThis is the first published study specifically targeting cardiac amyloidosis screening in patients presenting with coronary artery disease.Screening for…

A multisociety expert consensus statement calls for wider implementation of enhanced radiation protection devices for cath lab operators. (JACC: Cardiovascular…

On July 9, 2026, AstraZeneca and Ionis reported that the phase 3 CARDIO-TTRansform trial of eplontersen (Wainua) did not meet its primary efficacy endpoint in…

Department of Vascular Surgery, Beijing Haidian Hospital, Beijing, People’s Republic of China; 2Department of Hematology, Beijing Chao-Yang Hospital, Capital…

Attruby (acoramidis), an approved therapy for transthyretin amyloid cardiomyopathy (ATTR-CM), may help preserve kidney function in adults with the rare heart…

IntroductionAmyloidosis of the heart is a rare but serious condition that can significantly impact your cardiovascular health. It involves an abnormal buildup of…